China NT Pharma Group Co., Ltd. (1011) AI Stock Analysis

• Market Cap: HK$566.37M
• Dividend Yield: N/A
• Average Volume (3M): 1.68M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.03
• Shares Outstanding: 674,246,030
• 10 Day Avg. Volume: 1,250,790
• 30 Day Avg. Volume: 1,683,352
• PEG Ratio: -0.07
• Price to Book (P/B): -0.17
• Price to Sales (P/S): 1.76
• P/FCF Ratio: -7.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: HK$0.50 ▼(-40.48% Downside)

The overall stock score is heavily influenced by the company's poor financial performance, which poses significant risks. Technical analysis indicates weak momentum, and valuation metrics are unattractive due to ongoing losses. These factors collectively result in a low overall score.

Positive Factors

Innovative Drug Development

The company's focus on innovative drug development positions it to capture new market opportunities and drive long-term growth in the pharmaceutical sector.

Diverse Revenue Streams

Diverse revenue streams from prescription and OTC products provide resilience against market fluctuations and support stable long-term income.

Strategic Partnerships

Strategic partnerships for co-development and licensing can enhance product offerings and provide additional revenue through shared sales and royalties.

Negative Factors

Declining Revenues

Declining revenues and negative net income indicate operational challenges and threaten the company's ability to sustain growth and profitability.

High Leverage

High leverage increases financial risk and limits flexibility, potentially impacting long-term financial stability and investment capacity.

Liquidity Challenges

Liquidity challenges, as evidenced by erratic cash flow, can hinder the company's ability to fund operations and invest in growth opportunities.

China NT Pharma Group Co., Ltd. Business Overview & Revenue Model

Company Description

China NT Pharma Group Co., Ltd. is a leading pharmaceutical company based in China, primarily engaged in the research, development, manufacturing, and marketing of a wide range of pharmaceutical products. The company operates in several key sectors, including prescription drugs, over-the-counter medications, and health supplements. NT Pharma focuses on innovative drug development and aims to produce high-quality, affordable healthcare solutions for various therapeutic areas, including infectious diseases, oncology, and chronic conditions.

How the Company Makes Money

China NT Pharma Group Co., Ltd. generates revenue through multiple streams, primarily by selling its pharmaceutical products to hospitals, pharmacies, and healthcare providers across China and other markets. The company earns income from prescription medications, which are often sold in bulk to healthcare institutions, as well as from over-the-counter products that cater directly to consumers. Additionally, NT Pharma may engage in partnerships with other pharmaceutical firms for co-development and licensing agreements, which can provide significant revenue through shared sales and royalties. The company's focus on research and development also positions it to capitalize on new drug approvals and market expansions, further contributing to its earnings.

China NT Pharma Group Co., Ltd. Financial Statement Overview

Summary

The company faces significant financial challenges, including declining revenues, persistent losses, high leverage, and insolvency risks. Operational inefficiencies and liquidity issues further exacerbate the financial instability, resulting in a low score.

Income Statement

The company's income statement reflects significant revenue volatility and sustained negative net income over the past years, with a particularly sharp decline in revenue in 2023. The gross profit margin has decreased over time, and the company has struggled to achieve positive EBIT, indicating operational inefficiencies. These factors contribute to a low score.

Balance Sheet

The balance sheet shows a concerning financial structure, with negative stockholders' equity indicating insolvency risk. The debt-to-equity ratio cannot be calculated due to negative equity, but the high level of debt relative to assets suggests significant leverage. These elements indicate financial instability, contributing to a low score.

Cash Flow

The cash flow statement reveals erratic cash flow from operations, with a significant decline in free cash flow in 2024. The absence of positive free cash flow growth and the inability to cover net income with operating cash flow highlight liquidity challenges. These factors contribute to a low score.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.66M	37.96M	7.37M	207.09M	226.70M	221.73M
Gross Profit	9.57M	5.26M	7.37M	125.29M	145.46M	134.90M
EBITDA	-7.35M	-8.65M	1.33M	10.39M	-17.78M	-52.76M
Net Income	-70.92M	-53.36M	-143.59M	-66.41M	-149.54M	-357.60M
Balance Sheet
Total Assets	344.41M	334.07M	329.12M	1.01B	955.36M	1.30B
Cash, Cash Equivalents and Short-Term Investments	4.63M	9.62M	1.52M	5.93M	9.44M	7.69M
Total Debt	316.72M	375.95M	344.94M	826.45M	832.11M	851.46M
Total Liabilities	621.29M	733.18M	668.69M	1.25B	1.17B	1.27B
Stockholders Equity	-276.88M	-399.11M	-339.56M	-241.66M	-211.38M	16.28M
Cash Flow
Free Cash Flow	-22.61M	-9.24M	37.58M	31.72M	-135.42M	2.36M
Operating Cash Flow	-22.56M	-9.07M	50.48M	36.21M	-134.78M	26.20M
Investing Cash Flow	-55.00K	-189.00K	-22.14M	4.53M	257.81M	595.60M
Financing Cash Flow	23.02M	12.65M	-28.97M	-46.68M	-124.80M	-624.25M

China NT Pharma Group Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.84
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1011, the sentiment is Positive. The current price of 0.84 is above the 20-day moving average (MA) of 0.83, above the 50-day MA of 0.80, and above the 200-day MA of 0.63, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.50 is Neutral, neither overbought nor oversold. The STOCH value of 71.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1011.

China NT Pharma Group Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8329	54 Neutral	HK$255.06M	39.23	0.72%	3.51%	-5.98%	-81.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1652	49 Neutral	HK$551.42M	-2.96	-40.38%	―	-43.46%	-96.48%
8622	48 Neutral	HK$206.19M	-39.22	-8.71%	―	2.54%	33.33%
0897	46 Neutral	HK$461.29M	-32.52	-1.16%	6.98%	59.60%	-351.02%
0455	41 Neutral	HK$221.45M	-3.48	-13.08%	―	-19.28%	-42.27%
1011	41 Neutral	HK$566.37M	-3.33	―	―	―	―

China NT Pharma Group Co., Ltd. Corporate Events

China NT Pharma Group Announces Key Corporate Governance Appointments

China NT Pharma Group Co., Ltd. has announced significant changes in its corporate governance structure with the appointment of Ms. Li Yifang as the company secretary, authorized representative, and agent for the acceptance of service of process and notices in Hong Kong, effective from November 25, 2025. This strategic appointment of Ms. Li, who brings extensive experience in regulatory compliance and corporate governance, is expected to enhance the company’s operational efficiency and strengthen its compliance framework, potentially impacting its positioning in the industry.

China NT Pharma Group Embraces AI for Orthopedic Market Transformation

China NT Pharma Group Co., Ltd. is transforming into a high-tech medical enterprise driven by artificial intelligence to adapt to market changes and capitalize on opportunities in China’s growing orthopedic market. The company aims to build a comprehensive healthcare ecosystem focusing on testing, treatment, and rehabilitation in bone health, leveraging AI technology and national orthopedic initiatives to ensure continued business development and provide end-to-end solutions.

China NT Pharma Announces Key Resignation

China NT Pharma Group Company Limited has announced the resignation of Mr. Cheng Cheung King from his roles as company secretary, authorised representative, and agent for acceptance of service of process and notices in Hong Kong, effective October 17, 2025. The company is actively seeking a suitable replacement for these positions and has expressed gratitude for Mr. Cheng’s contributions during his tenure.

China NT Pharma Group Shifts Focus to Smart Health Ecosystem Amid Financial Restructuring

China NT Pharma Group Co., Ltd. has announced strategic measures to enhance its business operations and financial stability. The company is focusing on developing a smart health ecosystem in the bone health sector, including testing, treatment, and rehabilitation services, which are expected to become core revenue streams. Additionally, the company has secured agreements with debtors to extend loan terms and has received financial support commitments from major shareholders to aid in its strategic transformation.